| |
Total (n = 822)
|
Tertile 1 (n = 274)
|
Tertile 2 (n = 274)
|
Tertile 3 (n = 274)
|
P value
|
|---|
|
Demographics
|
|
Male
|
607 (73.8)
|
187 (68.3)
|
206 (75.2)
|
214 (78.1)
|
0.026
|
|
Physical activity, %
|
11.0 ± 5.8
|
4.9 ± 2.0
|
10.6 ± 1.5
|
17.5 ± 3.9
|
< 0.001
|
|
Age at implantation, years
|
60.8 ± 13.8
|
65.5 ± 13.2
|
61.1 ± 13.4
|
55.7 ± 13.1
|
< 0.001
|
|
BMI, kg/m2
|
23.6 ± 3.4
|
23.5 ± 3.7
|
23.5 ± 3.5
|
23.8 ± 3.4
|
0.293
|
|
Primary prevention
|
434 (52.8)
|
146 (53.3)
|
146 (53.3)
|
142 (51.8)
|
0.925
|
|
NYHA, class I–II
|
420 (51.1)
|
106 (38.7)
|
143 (52.2)
|
171 (62.4)
|
< 0.001
|
|
CRTD
|
217 (26.4)
|
82 (29.9)
|
76 (27.7)
|
59 (21.5)
|
0.069
|
|
Comorbidities
|
|
Ischemic cardiomyopathy
|
281 (34.2)
|
115 (42.0)
|
103 (37.6)
|
63 (23.0)
|
< 0.001
|
|
Hypertension
|
259 (31.5)
|
92 (33.6)
|
96 (35.0)
|
71 (25.9)
|
0.047
|
|
Diabetes
|
78 (9.5)
|
39 (14.2)
|
20 (7.3)
|
19 (6.9)
|
0.005
|
|
Stroke
|
16 (1.9)
|
10 (3.7)
|
3 (1.1)
|
3 (1.1)
|
0.044
|
|
Atrial fibrillation
|
90 (10.9)
|
33 (12.0)
|
31 (11.3)
|
26 (9.5)
|
0.615
|
|
Valvular disease
|
20 (2.4)
|
9 (3.28)
|
8 (2.92)
|
3 (1.09)
|
0.204
|
|
Prior myocardial infarction
|
128 (15.6)
|
60 (21.9)
|
45 (16.4)
|
23 (8.4)
|
< 0.001
|
|
Pre-implant syncope
|
175 (21.3)
|
57 (20.8)
|
52 (19.0)
|
66 (24.1)
|
0.334
|
|
Echocardiography
|
|
LVEF, %
|
42.7 ± 14.9
|
40.2 ± 14.6
|
42.9 ± 14.5
|
44.9 ± 15.3
|
< 0.001
|
|
LVEDD, mm
|
58.6 ± 13.1
|
58.9 ± 12.0
|
58.7 ± 13.6
|
58.1 ± 13.6
|
0.586
|
|
Medication
|
|
Beta-blockers
|
507 (61.7)
|
169 (61.7)
|
167 (61.0)
|
171 (62.4)
|
0.940
|
|
ACEIs/ARBs
|
321 (39.1)
|
116 (42.3)
|
106 (38.7)
|
99 (36.1)
|
0.327
|
|
Aldosterone antagonists
|
295 (35.9)
|
14 (45.3)
|
96 (35.0)
|
75 (27.4)
|
< 0.001
|
|
Statins
|
192 (23.4)
|
71 (25.9)
|
65 (23.7)
|
56 (2.4)
|
0.313
|
|
Loop diuretics
|
340 (41.4)
|
134 (48.9)
|
119 (43.4)
|
87 (31.8)
|
< 0.001
|
|
Digoxins
|
170 (20.7)
|
68 (24.8)
|
54 (19.7)
|
48 (17.5)
|
0.096
|
|
Amiodarone
|
250 (30.4)
|
87 (31.8)
|
84 (30.7)
|
79 (28.8)
|
0.755
|
- Abbreviations: ACEIs angiotensin-converting enzyme inhibitors, ARBs angiotensin receptor blockers, BMI Body Mass Index, CRTD cardiac resynchronization therapy and implantable cardioverter-defibrillator, LVEDD left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, NYHA class New York Heart Association class
